Could blocking TL1A stop skin scarring in scleroderma? early lab study hints at possibility
NCT ID NCT07642297
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test if blocking a protein called TL1A can reverse skin scarring in systemic sclerosis, a rare autoimmune disease. Researchers will take blood and skin samples from 10 patients with early diffuse scleroderma and 10 healthy people. They will treat the samples in the lab to see if blocking TL1A reduces immune activity, blood vessel damage, and fibrosis. This is a very early, proof-of-concept study — no treatment is given to participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TL1A neutralizing antibody and DR3 silencing (in lab, not given to participants)
- What this could lead to
- If successful, this could point toward a new treatment target for systemic sclerosis and other fibrotic diseases.
- What could go wrong
- This is a very early, small lab study using cells and skin samples, not a treatment trial. Results may not translate to real patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Immunorheumatology Unit, Fondazione Policlinico Universitario Campus Bio-Medico
Rome, Italy, 00128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.